Strengths and Limitations of Using the Polypill in Cardiovascular Prevention
Citations Over TimeTop 10% of 2017 papers
Abstract
Several short and intermediate to long-term studies with different brands of polypills have analysed the impact of polypill in phase II and III trials. The strengths of polypill that have emerged include better adherence, equivalent or better risk factor control and quality of life among polypill users as compared to usual care. The lurking limitations include difficulty with dose adjustment to targets, fear of mass medicalisation and low acceptability among physicians. The current literature supports polypill use in reducing blood pressure and cholesterol levels for CVD prevention with improvement in adherence to medication. However, the long-term outcome of polypill on CVD events and mortality are unavailable and are currently being studied in clinical trials.
Related Papers
- → Could the polypill improve adherence? The patient perspective(2013)35 cited
- [Are we ready to prescribe a polypill to our patients?].(2012)
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)
- → Examining the Use of a Polypill in Cardiovascular Disease Prevention(2023)